Search Results - "Hauser, Joana"

Cross-Coupling Reactions of 5‑Bromo-1,2,3-triazine by Hoff, Lukas V., Hauser, Joana M., Gademann, Karl

“…An efficient Pd catalyzed cross-coupling method for 5-bromo-1,2,3-triazine is described. Optimization of the reaction conditions allowed for the preparation of…”
Get full text

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer by Smyth, Lillian M., Batist, Gerald, Meric-Bernstam, Funda, Kabos, Peter, Spanggaard, Iben, Lluch, Ana, Jhaveri, Komal, Varga, Andrea, Wong, Andrea, Schram, Alison M., Ambrose, Helen, Carr, T. Hedley, de Bruin, Elza C., Salinas-Souza, Carolina, Foxley, Andrew, Hauser, Joana, Lindemann, Justin P. O., Maudsley, Rhiannon, McEwen, Robert, Moschetta, Michele, Nikolaou, Myria, Schiavon, Gaia, Razavi, Pedram, Banerji, Udai, Baselga, José, Hyman, David M., Chandarlapaty, Sarat

“…Five to ten percent of ER+ metastatic breast cancer (MBC) tumors harbor somatic PTEN mutations. Loss of function of this tumor-suppressor gene defines a highly…”
Get full text

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity by Sacco, Antonio, Federico, Cinzia, Todoerti, Katia, Ziccheddu, Bachisio, Palermo, Valentina, Giacomini, Arianna, Ravelli, Cosetta, Maccarinelli, Federica, Bianchi, Giada, Belotti, Angelo, Ribolla, Rossella, Favasuli, Vanessa, Revenko, Alexey S., Macleod, A. Robert, Willis, Brandon, Cai, Hongbo, Hauser, Joana, Rooney, Claire, Willis, Sophie E., Martin, Philip Lloyd, Staniszewska, Anna, Ambrose, Helen, Hanson, Lyndsey, Cattaneo, Chiara, Tucci, Alessandra, Rossi, Giuseppe, Ronca, Roberto, Neri, Antonino, Mitola, Stefania, Bolli, Niccolò, Presta, Marco, Moschetta, Michele, Ross, Sarah, Roccaro, Aldo M.

“…Alterations in KRAS have been identified as the most recurring somatic variants in the multiple myeloma (MM) mutational landscape. Combining DNA and RNA…”
Get full text

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer by Smyth, Lillian M., Tamura, Kenji, Oliveira, Mafalda, Ciruelos, Eva, Mayer, Ingrid A., Sablin, Marie-Paule, Biganzoli, Laura, Ambrose, Helen, Ashton, Jack, Barnicle, Alan, Cashell, Des, Corcoran, Claire, de Bruin, Elza C., Foxley, Andrew, Hauser, Joana, Lindemann, Justin P.O., Maudsley, Rhiannon, McEwen, Robert, Moschetta, Michele, Pass, Martin, Rowlands, Vicky, Schiavon, Gaia, Banerji, Udai, Scaltriti, Maurizio, Taylor, Barry S., Chandarlapaty, Sarat, Baselga, José, Hyman, David M.

Get full text

Abstract P1-19-05: Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER+ metastatic breast cancer by Smyth, Lillian M, Batist, Gerald, Meric-Bernstam, Funda, Kabos, Peter, Spanggaard, Iben, Lluch, Ana, Schram, Alison, Varga, Andrea, Wong, Andrea, Ambrose, Helen, Barnicle, Alan, Carr, T. Hedley, de Bruin, Elza C, Salinas-Souza, Carolina, Foxley, Andrew, Hauser, Joana, Lindemann, Justin PO, Maudsley, Rhiannon, McEwen, Robert, Moschetta, Michele, Roudier, Martine, Schiavon, Gaia, Razavi, Pedram, Banerji, Udai, Chandarlapaty, Sarat, Baselga, José, Hyman, David M

“…Abstract Background: Loss of function in the tumor suppressor gene, PTEN, activates PI3K/AKT signaling, driving tumor growth. Somatic mutations in PTEN occur…”
Get full text

Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma by Sacco, Antonio, Federico, Cinzia, Todoerti, Katia, Ziccheddu, Bachisio, Giacomini, Arianna, Ravelli, Cosetta, Maccarinelli, Federica, Bianchi, Giada, Belotti, Angelo, Ribolla, Rossella, Favasuli, Vanessa, Revenko, Alexey, MacLeod, A. Robert, Willis, Brandon, Cai, Hongoo, Hauser, Joana, Rooney, Claire, Ambrose, Helen, Staniszewska, Anna, Hanson, Lyndsey, Rossi, Giuseppe, Ronca, Roberto, Neri, Antonino, Mitola, Stefania, Bolli, Niccolò, Presta, Marco, Moschetta, Michele, Ross, Sarah, Roccaro, Aldo M.

“…INTRODUCTION. The multiple myeloma (MM) mutational landscape has identified KRAS as the most recurring somatic variant, observed in around 26% of cases,…”
Get full text

BRAF +/- MEK inhibition in patients (pts) with BRAF-mutant (mut) metastatic colorectal cancer (mCRC): The Sarah Cannon Research Institute UK’s experience by Uccello, Mario, Moschetta, Michele, Mak, Gabriel, Martynyuk, Nataliya, Hauser, Joana, Bassett, Sian, Voskoboynik, Mark, Lemech, Charlotte, Rafii, Saeed, Arkenau, Hendrik-Tobias

“…Abstract only 645 Background: Activating V600 BRAF mutations are detectable in around 10% of mCRC pts and are associated with poor prognosis. Low response…”
Get full text

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K -Mutant, ER-Positive Metastatic Breast Cancer by Smyth, Lillian M, Tamura, Kenji, Oliveira, Mafalda, Ciruelos, Eva M, Mayer, Ingrid A, Sablin, Marie-Paule, Biganzoli, Laura, Ambrose, Helen J, Ashton, Jack, Barnicle, Alan, Cashell, Des D, Corcoran, Claire, de Bruin, Elza C, Foxley, Andrew, Hauser, Joana, Lindemann, Justin P O, Maudsley, Rhiannon, McEwen, Robert, Moschetta, Michele, Pass, Martin, Rowlands, Vicky, Schiavon, Gaia, Banerji, Udai, Scaltriti, Maurizio, Taylor, Barry S, Chandarlapaty, Sarat, Baselga, José, Hyman, David M

“…The activating mutation occurs in approximately 7% of estrogen receptor-positive (ER ) metastatic breast cancer (MBC). We report, from a multipart,…”
Get full text

Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer by Moschetta, Michele, Mak, Gabriel, Hauser, Joana, Davies, Catriona, Uccello, Mario, Arkenau, Hendrik-Tobias

“…Targeting BRAF V600E mutation has been proven effective in the treatment of several types of cancer. In endometrial adenocarcinoma, the BRAF V600E mutation has…”
Get full text

Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer by Moschetta, Michele, Mak, Gabriel, Hauser, Joana, Davies, Catriona, Uccello, Mario, Arkenau, Hendrik-Tobias

“…BACKGROUNDTargeting BRAF V600E mutation has been proven effective in the treatment of several types of cancer. In endometrial adenocarcinoma, the BRAF V600E…”
Get full text